From what we can see, insiders were net buyers in Standard BioTools Inc.'s (NASDAQ:LAB ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it.    

Although we don't think shareholders should simply follow insider transactions,  we do think it is perfectly logical to keep tabs on what insiders are doing.

Standard BioTools Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider purchase was by Chief Financial Officer Jeffrey Black for US$194k worth of shares, at about US$2.29 per share.    That implies that an insider found the current price of US$2.52 per share to be enticing.  While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future.  We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price.   In this case we're pleased to report that the insider bought shares at close to current prices.  Jeffrey Black was the only individual insider to buy during the last year.    

The chart below shows insider transactions (by companies and individuals) over the last year.  If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

NasdaqGS:LAB Insider Trading Volume April 22nd 2024

Standard BioTools is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Does Standard BioTools Boast High Insider Ownership?

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own.  I reckon it's a good sign if insiders own a significant number of shares in the company.   Insiders own 1.0% of Standard BioTools shares, worth about US$9.2m, according to our data.  Whilst better than nothing, we're not overly impressed by these holdings.  

What Might The Insider Transactions At Standard BioTools Tell Us?

It doesn't really mean much that no insider has traded Standard BioTools shares in the last quarter.    However, our analysis of transactions over the last year is heartening.   While we have no worries about the insider transactions, we'd be more comfortable if they owned more Standard BioTools stock.      In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Standard BioTools.    You'd be interested to know, that we found 2 warning signs for Standard BioTools and we suggest you have a look.  

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.